Trending...
- Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
- OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
- Applicants Sought for the Tacoma Arts Commission and the Tacoma Creates Advisory Board
SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial availability of the Mouse Whole Transcriptome Atlas (WTA) for spatial analysis research using the GeoMx® Digital Spatial Profiler (DSP). This launch extends the GeoMx RNA portfolio, which combines the power of spatial biology and Next Generation Sequencing (NGS), to enable full transcriptome spatial RNA and high-plex protein analysis on the GeoMx DSP.
The GeoMx Mouse WTA provides an unbiased, spatial view of all protein-coding genes and is designed for NGS readout on Illumina sequencers. The WTA extends the GeoMx RNA Assay portfolio from a focus on oncology and immunology to new applications in neuroscience, developmental biology, and additional diverse fields. The mouse WTA utilizes the same workflow and chemistry as other GeoMx products to enable robust and sensitive performance in formalin-fixed paraffin-embedded (FFPE) or Fresh Frozen samples.
"The ability to study – with high sensitivity – regions near plaque formations in Alzheimer's disease mouse models is enabling important findings, including our recent identification of a microglial spatial signature, for example," said Dr. Michael Sasner, senior research scientist and MODEL-AD Center manager at The Jackson Laboratory. "These studies in novel mouse models should enable MODEL-AD to understand how the underlying biological mechanisms of AD may vary across brain regions with age, and to map where AD-related changes in expression start and how they spread with disease progression."
More on Washingtoner
"The GeoMx Mouse WTA is a key milestone for NanoString, bringing unbiased RNA profiling for the primary animal model for discovery research, which represents about 30% of the addressable market," said Chad Brown, senior vice president of Sales and Marketing, NanoString. "The strong enthusiasm for the products in our Technology Access Program highlights the appetite for whole transcriptome spatial analysis on GeoMx DSP."
The GeoMx Mouse WTA platform provides the opportunity to examine the relationship between pathology and gene expression within a tissue section. This technology enables measurement of all gene activity in tissue sections, across brain regions and ages, and to map where disease-related changes in expression occur.
To learn more about NanoString's GeoMx Digital Spatial Profiler, please visit https://www.nanostring.com/products/geomx-digital-spatial-profiler/geomx-dsp.
About NanoString Technologies, Inc.
NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company's nCounter® Analysis System is used in life sciences research and has been cited in more than 4,300 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's GeoMx® Digital Spatial Profiler enables highly multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.
More on Washingtoner
For more information, please visit www.nanostring.com.
NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
The GeoMx Mouse WTA provides an unbiased, spatial view of all protein-coding genes and is designed for NGS readout on Illumina sequencers. The WTA extends the GeoMx RNA Assay portfolio from a focus on oncology and immunology to new applications in neuroscience, developmental biology, and additional diverse fields. The mouse WTA utilizes the same workflow and chemistry as other GeoMx products to enable robust and sensitive performance in formalin-fixed paraffin-embedded (FFPE) or Fresh Frozen samples.
"The ability to study – with high sensitivity – regions near plaque formations in Alzheimer's disease mouse models is enabling important findings, including our recent identification of a microglial spatial signature, for example," said Dr. Michael Sasner, senior research scientist and MODEL-AD Center manager at The Jackson Laboratory. "These studies in novel mouse models should enable MODEL-AD to understand how the underlying biological mechanisms of AD may vary across brain regions with age, and to map where AD-related changes in expression start and how they spread with disease progression."
More on Washingtoner
- International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
- Boston Industrial Solutions Introduces Personalized Printing Training
- Century Fasteners de Mexico Exhibiting at the 2026 Automotive & Aerospace Nearshoring Summit
- Spokane: Funding Available for Tourism and Culture Investment Grants
- Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
"The GeoMx Mouse WTA is a key milestone for NanoString, bringing unbiased RNA profiling for the primary animal model for discovery research, which represents about 30% of the addressable market," said Chad Brown, senior vice president of Sales and Marketing, NanoString. "The strong enthusiasm for the products in our Technology Access Program highlights the appetite for whole transcriptome spatial analysis on GeoMx DSP."
The GeoMx Mouse WTA platform provides the opportunity to examine the relationship between pathology and gene expression within a tissue section. This technology enables measurement of all gene activity in tissue sections, across brain regions and ages, and to map where disease-related changes in expression occur.
To learn more about NanoString's GeoMx Digital Spatial Profiler, please visit https://www.nanostring.com/products/geomx-digital-spatial-profiler/geomx-dsp.
About NanoString Technologies, Inc.
NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company's nCounter® Analysis System is used in life sciences research and has been cited in more than 4,300 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's GeoMx® Digital Spatial Profiler enables highly multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.
More on Washingtoner
- FOCUS Names Mark Phillips Senior Vice President of Business Development
- Notaron Expands Online Notarization Access Following Wisconsin Approval
- Wings Air Helicopters Selected to Support VIP Transportation for Resorts World in New York
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
- Spokane: Construction Will Require Temporary Browne Street Lane Reductions
For more information, please visit www.nanostring.com.
NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
0 Comments
Latest on Washingtoner
- Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
- Pebble Photo Booths Brings Modern Photo Experiences to Vancouver, Washington
- Spokane: Flags at Half-Staff in Remembrance of 9/11 Victims
- Haven Treatment Center Now In-Network with First Choice, Expanding Access to Youth Health
- Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
- City of Spokane Launches 'Emergency Streets' Pilot Program
- Spokane: City Seeks Feedback on Future Land Use Map
- Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany
- Longevity Academy Announces J.P. Medved of Longevity Advice as Next Guest in the Longevity Leaders
- Medcurity Introduces a Better Way for Healthcare and Its Vendors to Build Trust
- Haven Treatment Center Now In-Network Partnership with Aetna, Expanding Access to Youth Health Care
- Applicants Sought for the Tacoma Arts Commission and the Tacoma Creates Advisory Board
- Spokane City Council Approves Emergency Tenant Protections
- HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
- Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
- Intelligence Daily Features Veteran Hollywood Producer Kirk Shaw On AI And The Future Of Entertainment
- OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
- P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport